Submitted by web@researchtop... on Thu, 01/10/2019 - 10:12
CME Test
Download PDF
CME information and faculty disclosures
Select publications
Related video program
Listen to streaming audio
right from your computer
Download program
to your desktop
Subscribe to podcast
to have this and future issues delivered to your iTunes library
Audio Highlights
Interview with Prof Eric Van Cutsem, MD, PhD
Track 1:
Biomarker assessment for patients with metastatic colorectal cancer (mCRC) in the first-line setting
Track 2:
Identification and therapeutic implications of rare genetic alterations for patients with mCRC
Track 3:
Effect of primary tumor sidedness on clinical decision-making for mCRC
Track 4:
Benefit with EGFR antibodies as first-line therapy for patients with mCRC and left-sided tumors
Track 5:
Sequencing therapies for patients with KRAS wild-type mCRC who have right-sided tumors
Track 6:
Selection of therapy for patients with mCRC according to KRAS mutation status
Track 7:
Therapeutic approach to mCRC with BRAF mutations
Track 8:
Side effects associated with BRAF/MEK inhibitors in combination with EGFR antibodies
Track 9:
Incidence and detection of HER2 amplifications in patients with mCRC
Track 10:
Management of HER2-amplified mCRC
Track 11:
Efficacy and tolerability of TAS-102 for mCRC
Track 12:
Efficacy and tolerability of regorafenib in the Phase II Regorafenib Dose Optimization Study (ReDOS)
Track 13:
Clinical implications of tumor cavitation induced by regorafenib
Track 14:
Phase II TASCO1 study evaluating the combination of TAS-102 or capecitabine with bevacizumab as first-line treatment for unresectable mCRC
Track 15:
Biology of microsatellite instability-high colorectal cancer and response to immune checkpoint inhibitors
Track 16:
Efficacy of anti-PD-1 antibodies as monotherapy or in combination with anti-CTLA-4 antibodies
Track 17:
Side effects associated with immune checkpoint inhibitors
Track 18:
Potential role of immune checkpoint inhibitors in combination with chemotherapy
Track 19:
Predictors of benefit with immune checkpoint inhibitors in CRC
Track 20:
Novel agents and approaches under investigation in the management of CRC
FACULTY
Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospital Gasthuisberg/Leuven
Leuven, Belgium
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida